Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XE28
|
| gptkbp:brand |
gptkb:Zykadia
|
| gptkbp:CASNumber |
1032900-25-6
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C28H36N5O3Cl
|
| gptkbp:hasSMILES |
CC(C)NC(=O)C1=CC2=C(C=C1)N=C(N2)N3CCN(CC3)C4=CC(=C(C=C4)Cl)OC
|
| https://www.w3.org/2000/01/rdf-schema#label |
ceritinib
|
| gptkbp:KEGGID |
D09913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ALK inhibitor
|
| gptkbp:molecularWeight |
558.07 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
57379345
CHEMBL2219158 DB09074 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue increased liver enzymes |
| gptkbp:target |
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
| gptkbp:UNII |
8L2S7309F8
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:ALK_rearrangement
|
| gptkbp:bfsLayer |
5
|